Respiratory Syncytial Virus Fusion Protein-encoding DNA Vaccine Is Less Effective in Conferring Protection against Inflammatory Disease than a Virus-like Particle Platform
- Author:
Young Man KWON
1
;
Hye Suk HWANG
;
Young Tae LEE
;
Ki Hye KIM
;
Youri LEE
;
Min Chul KIM
;
Yu Na LEE
;
Fu Shi QUAN
;
Martin L. MOORE
;
Sang Moo KANG
Author Information
- Publication Type:Original Article
- Keywords: RSV; F-VLP; F-DNA; Vaccine enhanced disease
- MeSH: Animals; B-Lymphocytes; Dendritic Cells; DNA; Germinal Center; Immunoglobulin G; Lung; Mice; Monocytes; Plasmids; Respiratory Syncytial Virus Vaccines; Respiratory Syncytial Viruses; T-Lymphocytes; Vaccination; Vaccines, Subunit; Viral Load; Weight Loss
- From:Immune Network 2019;19(3):e18-
- CountryRepublic of Korea
- Language:English
- Abstract: Formalin-inactivated respiratory syncytial virus (RSV) vaccination causes vaccine-enhanced disease (VED) after RSV infection. It is considered that vaccine platforms enabling endogenous synthesis of RSV immunogens would induce favorable immune responses than non-replicating subunit vaccines in avoiding VED. Here, we investigated the immunogenicity, protection, and disease in mice after vaccination with RSV fusion protein (F) encoding plasmid DNA (F-DNA) or virus-like particles presenting RSV F (F-VLP). F-DNA vaccination induced CD8 T cells and RSV neutralizing Abs, whereas F-VLP elicited higher levels of IgG2a isotype and neutralizing Abs, and germinal center B cells, contributing to protection by controlling lung viral loads after RSV challenge. However, mice that were immunized with F-DNA displayed weight loss and pulmonary histopathology, and induced F specific CD8 T cell responses and recruitment of monocytes and plasmacytoid dendritic cells into the lungs. These innate immune parameters, RSV disease, and pulmonary histopathology were lower in mice that were immunized with F-VLP after challenge. This study provides important insight into developing effective and safe RSV vaccines.
